Gilead officer sells 3,000 shares under plan

GILEAD SCIENCES, INC.

Available on EDGAR 09/16/2026 - 04:28 PM EDT Accepted by SEC EDGAR 09/16/2026 - 04:27 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

GILEAD SCIENCES, INC. (GILD) reports that Chief Commercial and Corporate Affairs Officer Johanna Mercier sold a total of 3,000 shares of common stock on September 15, 2026 in three open-market or private transactions. These trades were made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025, with sale prices ranging from $143.16 to $144.775 per share for portions of the shares. The filing does not state her remaining holdings.

Insider Trade Summary 10b5-1

Net Seller: 3,000 shares

Net Sell 3 txns

Insider Mercier Johanna

Role Chief Comm & Corp Aff Officer

Sold 3,000 shs ($433K)

Share of Position Sold 2.5%

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	1,600	$143.6917	$230K
Sale	Common Stock F1, F3	800	$144.4569	$116K
Sale	Common Stock F1	600	$145.29	$87K

Holdings After Transaction: Common Stock — 116,684 shares (Direct)

Holdings Before and After: Common Stock, 119,684 to 116,684 shares (Direct)

Other Insiders: 4 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (3)

1. F1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.
2. F2. Sale prices for the transactions reported range from $143.16 to $144.15. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
3. F3. Sale prices for the transactions reported range from $144.26 to $144.775. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

Key Figures

Shares sold: 3,000 shares Sale price range (first sale group): $143.16–$144.15 per share Sale price range (second sale group): $144.26–$144.775 per share +2 more

5 metrics

Shares sold 3,000 shares Total Gilead common shares sold by Johanna Mercier on September 15, 2026

Sale price range (first sale group) $143.16–$144.15 per share Price range for portions of the reported sales referenced in a footnote

Sale price range (second sale group) $144.26–$144.775 per share Price range for additional portions of the reported sales referenced in a footnote

Rule 10b5-1 plan adoption date February 20, 2025 Date the trading plan governing these sales was adopted

Individual transaction sizes 1,600; 800; 600 shares Share counts in the three reported sales of Gilead common stock

Key Terms

Rule 10b5-1 trading plan, open market or private transaction

2 terms

Rule 10b5-1 trading plan regulatory

"The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open market or private transaction financial

"Sale in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did GILD disclose for Johanna Mercier?

Gilead disclosed that Chief Commercial and Corporate Affairs Officer Johanna Mercier sold 3,000 shares of GILD common stock on September 15, 2026 in three reported open-market or private transactions under a pre-arranged Rule 10b5-1 trading plan.

At what prices were the 3,000 GILD shares sold by Johanna Mercier?

The sales on September 15, 2026 occurred at prices that, for portions of the shares, ranged from $143.16 to $144.775 per share, according to the transaction footnotes. The filing indicates full price-by-block details are available to the SEC, the issuer, or shareholders on request.

Were Johanna Mercier’s GILD share sales under a Rule 10b5-1 plan?

Yes. A footnote states the transactions were made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025, indicating they were pre-arranged rather than newly decided at the time of sale.

How many separate GILD transactions did Johanna Mercier report on this Form 4?

The Form 4 reports three separate non-derivative transactions, all involving sales of Gilead common stock on September 15, 2026, totaling 3,000 shares sold.

Does the filing show Johanna Mercier’s GILD holdings after these sales?

No. Each reported transaction lists the number of shares sold, but the line for shares owned directly after the transactions is left blank, so her post-transaction GILD holdings are not stated in this Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mercier Johanna

(Last) (First) (Middle)

GILEAD SCIENCES, INC.

333 LAKESIDE DRIVE

(Street)

FOSTER CITY CALIFORNIA 94404

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Comm & Corp Aff Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/15/2026		S(1)		1,600	D	$143.6917(2)	118,084	D
Common Stock	09/15/2026		S(1)		800	D	$144.4569(3)	117,284	D
Common Stock	09/15/2026		S(1)		600	D	$145.29	116,684	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

2. Sale prices for the transactions reported range from $143.16 to $144.15. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

3. Sale prices for the transactions reported range from $144.26 to $144.775. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

Remarks:

	/s/ Amy Kim by Power of Attorney for Johanna Mercier	09/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)